431 related articles for article (PubMed ID: 20099973)
21. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
[TBL] [Abstract][Full Text] [Related]
22. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
[TBL] [Abstract][Full Text] [Related]
23. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
[TBL] [Abstract][Full Text] [Related]
24. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
[TBL] [Abstract][Full Text] [Related]
25. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.
Smadja NV; Leroux D; Soulier J; Dumont S; Arnould C; Taviaux S; Taillemite JL; Bastard C
Genes Chromosomes Cancer; 2003 Nov; 38(3):234-9. PubMed ID: 14506697
[TBL] [Abstract][Full Text] [Related]
26. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
27. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
28. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
[TBL] [Abstract][Full Text] [Related]
29. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].
Decaux O; Lodé L; Minvielle S; Avet-Loiseau H
Rev Med Interne; 2007 Oct; 28(10):677-81. PubMed ID: 17559979
[TBL] [Abstract][Full Text] [Related]
30. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
31. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
32. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
Li C; Chen L; Gao X; Qu X; Shen W; Yang R; Zhang R; Qiu H; Xu J; Lu H; Li J
Leuk Lymphoma; 2011 Feb; 52(2):260-4. PubMed ID: 21133734
[TBL] [Abstract][Full Text] [Related]
33. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
[TBL] [Abstract][Full Text] [Related]
34. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
[TBL] [Abstract][Full Text] [Related]
35. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.
Avet-Loiseau H; Brigaudeau C; Morineau N; Talmant P; Laï JL; Daviet A; Li JY; Praloran V; Rapp MJ; Harousseau JL; Facon T; Bataille R
Genes Chromosomes Cancer; 1999 Jan; 24(1):9-15. PubMed ID: 9892103
[TBL] [Abstract][Full Text] [Related]
36. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
Fonseca R; Debes-Marun CS; Picken EB; Dewald GW; Bryant SC; Winkler JM; Blood E; Oken MM; Santana-Dávila R; González-Paz N; Kyle RA; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR
Blood; 2003 Oct; 102(7):2562-7. PubMed ID: 12805059
[TBL] [Abstract][Full Text] [Related]
37. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
38. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
[TBL] [Abstract][Full Text] [Related]
39. [Detection of chromosomal aberrations in multiple myeloma with fluorescence in situ hybridization].
Cao P; Chen F; Cheng Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 37(10):983-9. PubMed ID: 23117450
[TBL] [Abstract][Full Text] [Related]
40. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]